Literature DB >> 8687416

Apolipoprotein J and Alzheimer's amyloid beta solubility.

E Matsubara1, C Soto, S Governale, B Frangione, J Ghiso.   

Abstract

Apolipoprotein J (apoJ) has been found associated with soluble amyloid beta (sA beta) in plasma and cerebrospinal fluid in normal individuals and co-deposited with fibrillar A beta in Alzheimer's cerebrovascular and parenchymal lesions. Although studies in vitro and in vivo indicate that apoJ is a major carrier protein for sA beta, its role in the fibrillogenesis process is not known. We report herein that apoJ in its native high-density lipoprotein lipidic environment is fully active to interact with A beta peptides. Furthermore, apoJ prevents aggregation and polymerization of synthetic A beta in vitro. The interaction was stable for at least 14 days at 37 degrees C in physiologic buffers, and the peptide retrieved after complex dissociation at low pH retained its inherent aggregation properties. In addition, the binding to apoJ protects synthetic A beta from proteolytic degradation; both A beta 1-42 and A beta 1-40 were more resistant to proteolysis by trypsin and chymotrypsin when complexed to apoJ. The data suggest that the interaction may preclude sA beta aggregation in biological fluids and point to a protecting role of apoJ for complexed A beta species.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8687416      PMCID: PMC1217400          DOI: 10.1042/bj3160671

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  37 in total

Review 1.  Alzheimer's disease from the perspective of the systemic and localized forms of amyloidosis.

Authors:  E M Castaño; B Frangione
Journal:  Brain Pathol       Date:  1991-07       Impact factor: 6.508

2.  The soluble form of Alzheimer's amyloid beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma.

Authors:  A Koudinov; E Matsubara; B Frangione; J Ghiso
Journal:  Biochem Biophys Res Commun       Date:  1994-12-15       Impact factor: 3.575

3.  Transthyretin sequesters amyloid beta protein and prevents amyloid formation.

Authors:  A L Schwarzman; L Gregori; M P Vitek; S Lyubski; W J Strittmatter; J J Enghilde; R Bhasin; J Silverman; K H Weisgraber; P K Coyle
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-30       Impact factor: 11.205

4.  Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments.

Authors:  J Ma; A Yee; H B Brewer; S Das; H Potter
Journal:  Nature       Date:  1994-11-03       Impact factor: 49.962

5.  Brain uptake of circulating apolipoproteins J and E complexed to Alzheimer's amyloid beta.

Authors:  B V Zlokovic; C L Martel; J B Mackic; E Matsubara; T Wisniewski; J G McComb; B Frangione; J Ghiso
Journal:  Biochem Biophys Res Commun       Date:  1994-12-15       Impact factor: 3.575

6.  The amino acid sequence of neuritic plaque amyloid from a familial Alzheimer's disease patient.

Authors:  T Wisniewski; M Lalowski; E Levy; M R Marques; B Frangione
Journal:  Ann Neurol       Date:  1994-02       Impact factor: 10.422

7.  Characterization of beta-amyloid peptide from human cerebrospinal fluid.

Authors:  C Vigo-Pelfrey; D Lee; P Keim; I Lieberburg; D B Schenk
Journal:  J Neurochem       Date:  1993-11       Impact factor: 5.372

8.  Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro.

Authors:  T Wisniewski; E M Castaño; A Golabek; T Vogel; B Frangione
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

9.  Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3.

Authors:  D A Sanan; K H Weisgraber; S J Russell; R W Mahley; D Huang; A Saunders; D Schmechel; T Wisniewski; B Frangione; A D Roses
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

10.  Complete cloning and sequencing of rat gp330/"megalin," a distinctive member of the low density lipoprotein receptor gene family.

Authors:  A Saito; S Pietromonaco; A K Loo; M G Farquhar
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

View more
  51 in total

Review 1.  The role of clusterin in Alzheimer's disease: pathways, pathogenesis, and therapy.

Authors:  Jin-Tai Yu; Lan Tan
Journal:  Mol Neurobiol       Date:  2012-01-25       Impact factor: 5.590

2.  CEREBRAL AMYLOID ANGIOPATHY AND ALZHEIMER'S DISEASE.

Authors:  Jorge Ghiso; Yasushi Tomidokoro; Tamas Revesz; Blas Frangione; Agueda Rostagno
Journal:  Hirosaki Igaku       Date:  2010-07-08

Review 3.  Disorder-to-order conformational transitions in protein structure and its relationship to disease.

Authors:  Paola Mendoza-Espinosa; Victor García-González; Abel Moreno; Rolando Castillo; Jaime Mas-Oliva
Journal:  Mol Cell Biochem       Date:  2009-04-09       Impact factor: 3.396

4.  Reduction in amyloid A amyloid formation in apolipoprotein-E-deficient mice.

Authors:  M S Kindy; D J Rader
Journal:  Am J Pathol       Date:  1998-05       Impact factor: 4.307

5.  Increased clusterin expression in Fuchs' endothelial dystrophy.

Authors:  Ula V Jurkunas; Maya S Bitar; Ian Rawe; Deshea L Harris; Kathryn Colby; Nancy C Joyce
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-03-31       Impact factor: 4.799

Review 6.  Immunization treatment approaches in Alzheimer's and prion diseases.

Authors:  Thomas Wisniewski; Einar M Sigurdsson
Journal:  Curr Neurol Neurosci Rep       Date:  2002-09       Impact factor: 5.081

7.  Clusterin associates with altered elastic fibers in human photoaged skin and prevents elastin from ultraviolet-induced aggregation in vitro.

Authors:  Elke Janig; Martin Haslbeck; Ariane Aigelsreiter; Nathalie Braun; Daniela Unterthor; Peter Wolf; Noor M Khaskhely; Johannes Buchner; Helmut Denk; Kurt Zatloukal
Journal:  Am J Pathol       Date:  2007-09-14       Impact factor: 4.307

8.  A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice.

Authors:  Marcin Sadowski; Joanna Pankiewicz; Henrieta Scholtzova; James A Ripellino; Yongsheng Li; Stephen D Schmidt; Paul M Mathews; John D Fryer; David M Holtzman; Einar M Sigurdsson; Thomas Wisniewski
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

9.  Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease.

Authors:  Denise Harold; Richard Abraham; Paul Hollingworth; Rebecca Sims; Amy Gerrish; Marian L Hamshere; Jaspreet Singh Pahwa; Valentina Moskvina; Kimberley Dowzell; Amy Williams; Nicola Jones; Charlene Thomas; Alexandra Stretton; Angharad R Morgan; Simon Lovestone; John Powell; Petroula Proitsi; Michelle K Lupton; Carol Brayne; David C Rubinsztein; Michael Gill; Brian Lawlor; Aoibhinn Lynch; Kevin Morgan; Kristelle S Brown; Peter A Passmore; David Craig; Bernadette McGuinness; Stephen Todd; Clive Holmes; David Mann; A David Smith; Seth Love; Patrick G Kehoe; John Hardy; Simon Mead; Nick Fox; Martin Rossor; John Collinge; Wolfgang Maier; Frank Jessen; Britta Schürmann; Reinhard Heun; Hendrik van den Bussche; Isabella Heuser; Johannes Kornhuber; Jens Wiltfang; Martin Dichgans; Lutz Frölich; Harald Hampel; Michael Hüll; Dan Rujescu; Alison M Goate; John S K Kauwe; Carlos Cruchaga; Petra Nowotny; John C Morris; Kevin Mayo; Kristel Sleegers; Karolien Bettens; Sebastiaan Engelborghs; Peter P De Deyn; Christine Van Broeckhoven; Gill Livingston; Nicholas J Bass; Hugh Gurling; Andrew McQuillin; Rhian Gwilliam; Panagiotis Deloukas; Ammar Al-Chalabi; Christopher E Shaw; Magda Tsolaki; Andrew B Singleton; Rita Guerreiro; Thomas W Mühleisen; Markus M Nöthen; Susanne Moebus; Karl-Heinz Jöckel; Norman Klopp; H-Erich Wichmann; Minerva M Carrasquillo; V Shane Pankratz; Steven G Younkin; Peter A Holmans; Michael O'Donovan; Michael J Owen; Julie Williams
Journal:  Nat Genet       Date:  2009-09-06       Impact factor: 38.330

10.  Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease.

Authors:  Ronald B DeMattos; Mark A O'dell; Maia Parsadanian; Jennie W Taylor; Judith A K Harmony; Kelly R Bales; Steven M Paul; Bruce J Aronow; David M Holtzman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-26       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.